To further evaluate the clinical utility of ATX, we systematically compared it with both tumor markers (AFP, PIVKA‐2) and fibrosis markers (HA, 4C7S, FIB‐4, M2BPGi) for post‐RFA recurrence prediction. This evidence concerns the gene AFP and neoplasm.